Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Pharmalink AB receives patent for Nefecon® principle. Japanese grant supports Asian partnering program.

Pharmalink AB completes Phase II clinical study with renal disease drug Nefecon

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2022